BioMotiv
Accelerating Breakthrough Discoveries into Medicines

News

News

Dual Therapeutics, a New Oncology Start-up, Is Launched by BioMotiv and the Icahn School of Medicine

CLEVELAND AND NEW YORK CITY – October 09, 2013

BioMotiv, a drug development accelerator based in Cleveland, and the Icahn School of Medicine at Mount Sinai, based in New York, are announcing the formation of Dual Therapeutics, a company focused on producing therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia.

Click to view full release